No EFS Benefit With Second-Line Tisa-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma
The median event-free survival was 3 months in both treatment arms.
Diagnosis & Disease Information
First-Line Ivosidenib Plus Azacitidine Prolonged Survival in IDH1-Mutated AML
The combination of ivosidenib plus azacitidine significantly prolonged OS with a median of 24.0 months compared with 7.9 months with placebo plus azacitidine.
Duration of TKI Treatment Predicts Early, Late Recurrence in Chronic Myeloid Leukemia
The underlying mechanisms of late recurrence must be investigated further, according to researchers.
Pola-R-CHP Outperforms Standard Care for Diffuse Large B-Cell Lymphoma
Patients who received Pola-R-CHP were less likely to need subsequent treatment compared with those who received standard R-CHOP.
Allo-HSCT Improves Survival in Patients With TP53-Mutated Acute Myeloid Leukemia
Researchers analyzed treatment trends and outcomes over time to identify the optimal management strategy for TP53-mutated AML.
Naratuximab Emtansine Plus Rituximab: A New Treatment Option for Rel/Ref Non-Hodgkin Lymphoma?
The median duration of response was not reached in patients with follicular lymphoma or diffuse large B-cell lymphoma.
Zanubrutinib Improves PFS, But May Not Improve OS, in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Researchers sought to determine whether zanubrutinib would improve survival in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
Low-Dose Inotuzumab Ozogamicin May Be Safe and Effective in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Researchers sought to determine whether a low dose of inotuzumab ozogamicin would be safe and effective in patients with relapsed/refractory ALL.
Racial/Ethnic and Socioeconomic Disparities in Outcomes Among Children With Acute Lymphoblastic Leukemia
Researchers sought to determine whether there are disparities by race/ethnicity and socioeconomic status in survival outcomes of children with ALL.
Adding Pevonedistat to Azacitidine Does Not Improve Outcomes for Patients With MDS/CMML and AML
Researchers sought to determine whether adding pevonedistat to azacitidine would improve outcomes for patients with higher-risk MDS, CMML, or AML.
- Loading...
Loading...
Next post in ASH 2021
Loading... 
Loading...